Compare AIRS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRS | PROF |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 243.2M |
| IPO Year | 2021 | 2017 |
| Metric | AIRS | PROF |
|---|---|---|
| Price | $4.14 | $7.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.3M | 84.0K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $151,818,000.00 | $16,098,000.00 |
| Revenue This Year | $5.19 | $92.40 |
| Revenue Next Year | $5.32 | $64.10 |
| P/E Ratio | ★ N/A | $37.74 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $1.51 | $3.92 |
| 52 Week High | $12.00 | $8.95 |
| Indicator | AIRS | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 71.04 | 57.00 |
| Support Level | $2.40 | $7.00 |
| Resistance Level | $6.90 | $7.97 |
| Average True Range (ATR) | 0.37 | 0.46 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 80.63 | 48.92 |
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.